Journal Article Summary
The article investigates a new method for delivering carteolol hydrochloride (CH), a medication used to lower intraocular pressure (IOP) in glaucoma patients. Traditional treatments, primarily eyedrops, often face challenges such as poor patient adherence and limited effectiveness due to the drug's rapid clearance from the eye. The study aims to compare the effectiveness of a transscleral sustained-release device, designed to deliver CH directly to the eye's posterior segment, against conventional eyedrop administration.
In this study, researchers created a device that releases CH over two weeks and tested its effectiveness in rabbits. They found that the transscleral device delivered CH to the retina and choroid, areas that eyedrops could not reach, while eyedrops primarily affected the anterior segment of the eye. Although the device reduced IOP significantly at one day post-implantation, this effect was not sustained over time. The concentration of CH in the aqueous humor was lower with the transscleral method compared to eyedrops, indicating a trade-off between effective delivery to the posterior segment and maintaining IOP reduction.
Despite promising results, the study has limitations, including the need for device replacement after the drug is depleted and potential risks associated with surgical implantation. Patients should discuss these findings with their healthcare providers, especially regarding the implications for glaucoma treatment and the potential benefits of sustained drug delivery systems. Understanding these new options may help improve adherence to treatment and overall management of eye health.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Hashikawa Yoshiko, Kato Yuki, Kaji Hirokazu, Abe Toshiaki, Nagai Nobuhiro. A comparative study between a transscleral sustained-release device and eyedrops on intraocular distribution of carteolol hydrochloride. Heliyon 2023. DOI: 10.1016/j.heliyon.2023.e14392. PMID: 36942217. PMCID: PMC10023953.
Featured Pill Pals Product
Bimatoprost 0.03% Eyelid Solution --- 5 ML --- Generic for Latisse --- Sandoz
Bimatoprost 0.03% Eyelid Solution — 5 ML — Generic for Latisse — Sandoz is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
